T1942 |
DMH-1
|
1206711-16-1
|
99.7%
|
|
DMH-1 is a potent and selective BMP inhibitor.
|
T8399 |
Crizotinib hydrochloride
|
1415560-69-8
|
99.67%
|
|
Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
|
T3079 |
GSK1838705A
|
1116235-97-2
|
99.63%
|
|
GSK1838705A is an effective IGF-1R inhibitor (IC50: 2.0 nM), modestly potent to IR (IC50: 1.6 nM) and ALK (IC50: 0.5 nM), respectively, and little inhibition to ...
|
T8387 |
Alectinib hydrochloride
|
1256589-74-8
|
99.61%
|
|
Alectinib hydrochloride (RO5424802 Hydrochloride) is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM)
|
T3678 |
Entrectinib
|
1108743-60-7
|
99.61%
|
|
Entrectinib (RXDX-101) is an inhibitor of TrkA (IC50: 1.7 nM), TrkB (IC50: 0.1 nM), and TrkC (IC50: 0.1 nM), as well as anaplastic lymphoma kinase (ALK; IC50: 1....
|
T10287 |
ALK2-IN-2
|
2254409-25-9
|
99.55%
|
|
ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) (IC50: 9 nM), inhibiting ALK2 700-fold more than ALK3.
|
T6496 |
Vactosertib
|
1352608-82-2
|
99.55%
|
|
Vactosertib (EW-7197) is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also kn...
|
T14997 |
Conteltinib
|
1384860-29-0
|
99.54%
|
|
Conteltinib (CT-707) is an enzyme inhibitor with antitumor activity targeting FAK, ALK, and Pyk2.Conteltinib exhibits significant inhibition of FAK, overcomes hy...
|
T4257 |
Belizatinib
|
1357920-84-3
|
99.48%
|
|
Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.
|
T1791 |
Ceritinib
|
1032900-25-6
|
99.46%
|
|
Ceritinib (LDK378) is a specific ALK inhibitor (IC50: 0.2 nM).
|
T1900 |
LDN-212854
|
1432597-26-6
|
99.38%
|
|
LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2...
|
T1661 |
Crizotinib
|
877399-52-5
|
99.35%
|
|
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
|
T2098 |
A 77-01
|
607737-87-1
|
99.31%
|
|
A 77-01 is a potent inhibitor of TGF-(beta) type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.
|
T22324 |
Ensartinib hydrochloride
|
2137030-98-7
|
99.29%
|
|
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known cr...
|
T1914 |
K02288
|
1431985-92-0
|
99.27%
|
|
K 02288 is a novel small molecule inhibitor of ALK1/2/3/6.
|
T9837 |
N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-bromoaniline
|
1352608-94-6
|
99.27%
|
|
Compound 12d is a potent ALK5 inhibitor with an IC50 of 7nM.
|
T9947 |
GW-6604
|
452342-37-9
|
99.26%
|
|
GW-6604 is an ALK5 inhibitor and shows clear antifibrotic effects resulting in liver function improvement.
|
T10759 |
CEP-28122 mesylate salt (1022958-60-6 free base)
|
T10759
|
99.19%
|
|
CEP-28122 mesylate salt (1022958-60-6 free base) is a highly selective orally active ALK inhibitor (IC50: 1.9 nM in an enzyme-based TRF assay).
|
T11184 |
EML4-ALK kinase inhibitor 1
|
1373409-08-5
|
99.14%
|
|
EML4-ALK kinase inhibitor 1 (EML4 ALK kinase inhibitor 1) is a potent oral active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lympho...
|
T1967 |
AZD-3463
|
1356962-20-3
|
99.13%
|
|
AZD-3463 (ALK/IGF1R inhibitor) , an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency.
|